Intestinal Flora Sequencing for Nasopharyngeal Carcinoma

Intestinal Flora Disruption and a Novel Intestinal Biomarker Associated With Nasopharyngeal Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04094545

Enrollment

568

Registered

2019-09-19

Start date

2018-08-01

Completion date

2019-05-30

Last updated

2019-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Keywords

Biomarker, nasopharyngeal carcinoma, familial, sporadic, intestinal flora

Brief summary

This study investigated the correlation between the changes in the intestinal flora and NPC by an examination of the intestinal flora and multiple clinical indicators of the blood of 8 carefully screened patients of familial NPC, 24 patients of sporadic NPC and 27 healthy controls and a comparison of the differences in their intestinal flora structures and biological functions. By analyzing the function of the intestinal floras of NPC patients, we aimed to provide a better biological marker for patients with familial and sporadic NPC and constructed a disease prediction model for high-risk populations.

Detailed description

Nasopharyngeal carcinoma (NPC) is a malignant nasopharyngeal disease with a complicated etiology that occurs mostly in southern China. Intestinal flora imbalance is believed to be associated with a variety of organ malignancies. Currently, the relationship between intestinal flora and NPC is not clear, although many studies have shown that intestinal flora can be used as a biomarker for many cancers and to predict cancer. To compare the differences in intestinal flora compositions and biological functions among patients with familial NPC (NPC\_F), patients with sporadic NPC (NPC\_S) and healthy controls (NOR), we compared the intestinal flora DNA sequencing and hematological testing results between every two groups using bioinformatic methods.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* NPC patients with a first degree family history of NPC * NPC patients without any kind of tumor family history

Exclusion criteria

* Informed refusal. * Lack of necessary tests and patient test information is not detailed

Design outcomes

Primary

Measure	Time frame	Description
family NPC patients	through study completion, an average of 1 year	NPC patients with a first degree NPC family history
sporadic NPC patients	through study completion, an average of 1 year	NPC patients without any tumor family history

Countries

China

Outcome results